Multiple sclerosis (Houndmills, Basingstoke, England) · 2015
Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uzawa Akiyuki, Mori Masahiro, Uchida Tomohiko, Masuda Hiroki, Ohtani Ryohei, Kuwabara Satoshi
Аннотация
BACKGROUND: Recently, new diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD) were published.
OBJECTIVE: Our primary aim was to evaluate the usefulness of the new diagnostic criteria in anti-aquaporin 4 (AQP4) antibody-negative cases.
METHODS: Consecutive 471 patients whose anti-AQP4 antibody was measured at Chiba University were reviewed.
RESULTS: Four anti-AQP4 antibody negative-patients, who fulfilled the new diagnostic criteria for NMOSD but not 2006 diagnostic criteria for neuromyelitis optica (NMO), were identified. They showed high cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels, an absence of oligoclonal bands and/or cloud-like enhancement on magnetic resonance imaging, which are compatible findings for NMO.
CONCLUSION: The new diagnostic criteria are clinically useful in seronegative NMOSD.
OBJECTIVE: Our primary aim was to evaluate the usefulness of the new diagnostic criteria in anti-aquaporin 4 (AQP4) antibody-negative cases.
METHODS: Consecutive 471 patients whose anti-AQP4 antibody was measured at Chiba University were reviewed.
RESULTS: Four anti-AQP4 antibody negative-patients, who fulfilled the new diagnostic criteria for NMOSD but not 2006 diagnostic criteria for neuromyelitis optica (NMO), were identified. They showed high cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels, an absence of oligoclonal bands and/or cloud-like enhancement on magnetic resonance imaging, which are compatible findings for NMO.
CONCLUSION: The new diagnostic criteria are clinically useful in seronegative NMOSD.